TSLPR-CART

TSLPR-CART is an autologous chimeric antigen receptor (CAR) T-cell therapy targeting the thymic stromal lymphopoietin receptor (TSLPR), which is encoded by the *CRLF2* gene. Developed by the National Cancer Institute (NCI), this therapy is specifically designed for the treatment of B-cell acute lymphoblastic leukemia (B-ALL) characterized by *CRLF2* rearrangements (CRLF2-R), which lead to the overexpression of TSLPR on the surface of leukemic blasts. The treatment process involves collecting a patient's T cells via leukapheresis, genetically engineering them to express a CAR specific for TSLPR, and re-infusing them into the patient following lymphodepleting chemotherapy. Once infused, the CAR-T cells recognize and bind to TSLPR-expressing cancer cells, triggering targeted cell lysis. It is currently being evaluated in Phase I clinical trials for safety and efficacy in adult patients with recurrent or refractory CRLF2-R/TSLPR-overexpressing B-ALL.

Other names

Anti-CRLF2-R/TSLPR CAR T cellsAnti-TSLPR CAR-TCRLF2-targeted CAR-TCRLF-2-targeted CAR-TCRLF 2-targeted CAR-T